 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
 |
|
|
||
About
HIFU |
||
|
About
Ablatherm |
||
|
Clinical
Information |
||
Clinical
Results
Large
Cohort Studies
Long
Term Results
Radiotherapy Failures
Safety Results |
||
|
Clinical
Trials |
||
|
||
|
Video
Clips |
||
 |
| You are here : Physicians > HIFU - Ablatherm > Clinical Results > Large Cohort Studies |
 |
|
 Studies with large cohort of patients
are available… |
| From 1995 to 1999, 559 prostate cancer patients were included in a European multi-centric study (1). Most of the patients (n=402) were T1-T2 prostate cancer patients treated with Ablatherm-HIFU as first choice therapy. In this T1-T2 population, negative biopsies were observed in 87.2% of the patients. At least 50% of the patients presented a nadir PSA at 0.1 or less after a complete treatment. |
 |
| A special highlight on the biopsy results according to the disease related initial risk level shows that 92,1 % of the low risk patients (cancer involving less than half a lobe, PSA <10ng/ml and Gleason sum lower or equal to 6) presented negative biopsies during their overall follow-up (up to 51 months). |
 |
| (1) C. Chaussy, S. Thüroff, G. Vallancien, W. Wieland, H.J. Kiel, A. Le Duc, F. Desgranchamps, J. de la Rosette, A. Gelet – High Intensity Focused Ultrrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study - The Journal Of Urology, October 2003, Vol. 17, 8:673 |
| Last update: April 2007 |
|
|
® Ablatherm
is aregistered trademark of EDAP. © Copyright 2007 EDAP. All rights reserved. |